On May 4, 2020 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported dates for new data to be presented in abstract presentations at three upcoming medical meetings, as well as a management presentation at an investor conference in Spring 2020 (Press release, Phio Pharmaceuticals, MAY 4, 2020, View Source [SID1234556950]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 2020 Annual Meeting

Title:

Adoptive Cell Therapy don’t over engineer it; Alternatives to gene editing to improve cell-based therapeutics for the treatment of cancer

Date:

Tuesday, May 12, 2020

Presenter:

Dr. Simon P. Fricker

Abstract number:

1179

* This will be a virtual event in 2020 due to the COVID-19 pandemic

ASCO20 Virtual Scientific Program

Title:

Intratumoral use of self-delivering RNAi to reprogram the tumor microenvironment and boost the antitumor response

Date:

Friday, May 29, 2020

Presenter:

Dr. Gerrit Dispersyn

Abstract number:

e15206

* This will be a virtual event in 2020 due to the COVID-19 pandemic

American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II

Title:

Intratumoral delivery of mPH-804 (TIGIT targeting INTASYL compound) inhibits tumor growth and confers an inflammatory tumor microenvironment

Date:

Monday, June 22, 2020

Session Title:

Immune Checkpoints 2

Presenter:

Dr. Simon P. Fricker

Abstract number:

5745

* This will be the second of two AACR (Free AACR Whitepaper) virtual annual meeting events being held in 2020 due to the COVID-19 pandemic

Sachs Associates 6th Annual Digital Immuno-oncology Innovation Forum

Date:

Wednesday, May 27, 2020

Time:

1:00 p.m. CST

Presenter:

Dr. Gerrit Dispersyn

Location:

* This will be a virtual event in 2020 due to the COVID-19 pandemic

The poster presentations and the corporate presentation will be made available under the "Investors – Events and Presentations" section of the Company’s website approximately one hour after each event.

On May 4, 2020 Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX) reported an update on its pilot clinical study to assess the unique characteristics of its fulvestrant product candidate, EA-114, which has the potential to enhance estrogen receptor ("ER") inhibition and improve patient outcomes (Press release, Eagle Pharmaceuticals, MAY 4, 2020, View Source [SID1234556949]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As discussed on our March 2nd earnings call, we have continued to refine our EA-114 program, collected additional pilot data, and are pleased with our progress. We have had two meetings with FDA and will request another meeting to discuss these data. With FDA’s guidance, we hope to move ahead with our plans. We look forward to providing additional updates on the progress of this potential drug treatment for hormone-receptor ("HR")-positive advanced breast cancer," stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.

"A substantial number of women with advanced HR-positive breast cancer receiving standard treatment experience early disease progression," said Adrian Hepner, Chief Medical Officer of Eagle Pharmaceuticals. "Low and inconsistent estrogen receptor inhibition often results in suboptimal treatment, which may lead to faster progression of the disease. Our research suggests that we may have a better approach."

About Fulvestrant

Fulvestrant, an estrogen receptor antagonist with no agonist properties, is approved by the FDA for the treatment of advanced hormone-related breast cancers. The therapeutic effect of fulvestrant involves its ability to competitively inhibit estrogen-stimulated cell division by binding to the ERs in cancer cells, which may reduce cancer cell proliferation.

Fulvestrant is indicated as a monotherapy treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy, or as a combination therapy for the treatment of: (1) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women, in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy, or (2) HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with palbociclib or abemaciclib, in women with disease progression after endocrine therapy.

About Breast Cancer

Breast cancer is the most commonly diagnosed cancer in women, with approximately 290,000 women diagnosed in the U.S. annually and more than 2.8 million breast cancer survivors in the U.S. today. HR-positive breast cancer is the most common clinical subtype, with the ER being expressed in approximately 75% of those diagnosed.

On May 4, 2020 Ribon Therapeutics, a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways, reported that Victoria Richon, Ph.D., President and CEO, will present at two upcoming virtual healthcare conferences (Press release, Ribon Therapeutics, MAY 4, 2020, View Source [SID1234556948]). Presentations will consist of a panel discussion and a corporate overview.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

31st Annual Cancer Progress Conference – May 5-6, 2020
Panel: Paradigm-shifting Platforms II, Non-IO: Targeting Better, Targeting the Intractable
Date: May 5, 2020
Time: 11:45 a.m. EDT

Bank of America Securities 2020 HealthCare Conference – May 12-14, 2020
Corporate Presentation
Date: May 12, 2020
Time: 5:00 p.m. EDT

On May 4, 2020 Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, reported that Company management will host a conference call and webcast on Monday, May 11, 2020 at 8:00 a.m. ET to review operating results for the first quarter ended March 31, 2020 (Press release, Sesen Bio, MAY 4, 2020, http://ir.elevenbio.com/news-releases/news-release-details/sesen-bio-host-conference-call-review-first-quarter-financial [SID1234556942]). The Company will also provide an update on the progress of manufacturing activities related to demonstrating analytical comparability between clinical batches of Vicinium and validation batches of Vicinium intended for potential future commercial use.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, please dial (844) 831-3025 (domestic) or (315) 625-6887 (international) and refer to conference ID 3780957. The webcast can be accessed in the Investor Relations section of the Company’s website at www.sesenbio.com. The replay of the webcast will be available in the investor section of the Company’s website at www.sesenbio.com for 60 days following the call.

About Vicinium

Vicinium, a locally administered fusion protein, is Sesen Bio’s lead product candidate being developed for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC). Vicinium is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A. Vicinium is constructed with a stable, genetically engineered peptide tether to ensure the payload remains attached until it is internalized by the cancer cell, which is believed to decrease the risk of toxicity to healthy tissues, thereby improving its safety. In prior clinical trials conducted by Sesen Bio, EpCAM has been shown to be overexpressed in NMIBC cells with minimal to no EpCAM expression observed on normal bladder cells. Sesen Bio is currently conducting the Phase 3 VISTA trial, designed to support the registration of Vicinium for the treatment of high-risk NMIBC in patients who have previously received a minimum of two courses of bacillus Calmette-Guérin (BCG) and whose disease is now BCG-unresponsive. Additionally, Sesen Bio believes that cancer cell-killing properties of Vicinium promote an anti-tumor immune response that may potentially combine well with immuno-oncology drugs, such as checkpoint inhibitors. The activity of Vicinium in BCG-unresponsive NMIBC is also being explored at the US National Cancer Institute in combination with AstraZeneca’s immune checkpoint inhibitor durvalumab.

On May 4, 2020 Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer and other indications, reported that it will host a first quarter 2020 investor call on Monday, May 11, 2020 at 8:00 AM EDT to discuss financial results and provide a corporate update (Press release, Pieris Pharmaceuticals, MAY 4, 2020, View Source [SID1234556941]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the call, participants may dial 877-407-8920 (Toll Free US & Canada) or 412-902-1010 (International) at least 10 minutes prior to the start of the call.

An archived replay of the call will be available for 30 days by dialing 877-660-6853 (Toll Free US & Canada) or 201-612-7415 (International) and providing the Conference ID #13661472.